FEMSelect develops EnPlace®, a minimally invasive, meshless system for pelvic floor ligament fixation cleared by the FDA to manage symptomatic uterine prolapse. The technology enables a procedure in under 30 minutes, and clinical studies report women can return to normal activities within a few days. FEMSelect has partnered with LiNA Medical USA and has spent the past year educating physicians on the technology. The company obtained a CMS procedure code earlier this year, enabling healthcare facilities to receive reimbursement for the procedure. EnPlace is currently available in more than 25 US states. FEMSelect plans to use the Series B proceeds to support growth and market penetration of EnPlace, primarily in the US; the company is led by Co-CEOs Debbie Garner and Renee Selman. POP Medical Solutions Ltd. develops NeuGuide, a minimally-invasive, meshless and dissectionless surgical system to treat pelvic organ prolapse (POP). NeuGuide combines a Nitinol-based anchor, surgical sutures and an innovative attachment method and has received FDA clearance. The device was tested in a 15-patient trial in Israel and is currently being used by US physicians in a post-marketing study. POP plans to use new funding to complete the post-marketing study, obtain European CE Mark certification, transfer the product to mass production, and build a US commercial organization for an early 2019 launch. CEO Deborah Garner leads the company and MABA founder Bernie Rudnick will join POP's board as part of the financing.

Total raised

$12M

Funding rounds

2

Latest round

Series B

Latest activity

Oct 2022